Mesoblast Limited

Mesoblast Limited is an Australian regenerative medicine company focused on developing and commercializing allogeneic (off-the-shelf) cellular medicines. The company's core mission is to address severe and life-threatening inflammatory conditions with significant unmet medical needs. Its global headquarters are located in Melbourne, Australia.

Mesoblast leverages a proprietary technology platform based on mesenchymal lineage cells, including Mesenchymal Precursor Cells (MPCs) and Mesenchymal Stem Cells (MSCs). Key product candidates include Ryoncil® (remestemcel-L), an FDA-approved therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children, with ongoing development for adult indications and other inflammatory diseases. The company is also advancing rexlemestrocel-L (MPC-06-ID) through Phase 3 clinical trials for chronic low back pain due to degenerative disc disease, and Revascor® (rexlemestrocel-L or MPC-150-IM) for advanced chronic heart failure, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Founded by CEO Dr. Silviu Itescu, Mesoblast is positioned as a global leader in allogeneic cellular medicines. In April 2026, the company announced it had completed patient recruitment for its pivotal Phase 3 clinical trial of rexlemestrocel-L for chronic low back pain, with top-line results anticipated in mid-2027 and a regulatory filing planned for Q3 2027. Ryoncil® generated net revenues of US$30.3 million in the March quarter of 2026, contributing to nearly US$100 million in total revenue since its launch. Mesoblast also recently acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform to enhance its cell products and received FDA clearance for a clinical trial of Ryoncil in children with Duchenne muscular dystrophy.